Female Reproductive System Carcinoma — Trials

Female Reproductive System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 458
Recruiting: 230
Ph III recruiting: 25
Growth YoY: +35.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (201)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05215574	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1	130	NGM Biopharmaceuticals, IncINDUSTRY	1	Oct 10, 2024	clinicaltrials
NCT04652076	GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab(GYNET)	active not recruiting	Phase 1 / Phase 2	240	NETRIS PharmaINDUSTRY	1	Oct 8, 2024